Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06702449 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
A Phase 1 study of Urinary Tract Infections, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 448
- Enrollment target
- 8
- Study locations
NCT06702449 is a Phase 1 study of Urinary Tract Infections that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 448 participants, roughly in line with the 445-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target. The trial reports 8 study locations across 6 states.
The verdict
NCT06702449, a Phase 1 study of Urinary Tract Infections, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 448 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Candidate UTI vaccine low dose formulation 1
- COMBINATION_PRODUCT Candidate UTI vaccine low dose formulation 2
- COMBINATION_PRODUCT Candidate UTI vaccine medium dose formulation 1
- COMBINATION_PRODUCT Candidate UTI vaccine medium dose formulation 2
- COMBINATION_PRODUCT Candidate UTI vaccine high dose formulation 1
Study Locations (8)
Washington
- GSK Investigational Site - Seattle
- GSK Investigational Site - Wenatchee
Other
- GSK Investigational Site - Johannesburg
- GSK Investigational Site - Soshanguve
Kansas
- GSK Investigational Site - Lenexa
New Jersey
- GSK Investigational Site - Secaucus
New York
- GSK Investigational Site - Rochester
Texas
- GSK Investigational Site - Weatherford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2024-11-19 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06702449
The ClinicalTrials.gov registry entry for NCT06702449 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 448 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 445-participant average among 34 other Urinary Tract Infections trials with a reported enrollment target. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Tract Infections appearing as the primary indexed condition, and to 5 interventions - of which Candidate UTI vaccine low dose formulation 1 is the first listed.
NCT06702449 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Washington, Other, Kansas.
Frequently Asked Questions
What is clinical trial NCT06702449 about?
NCT06702449 is a clinical study titled "A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age". The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
What is the current status of trial NCT06702449?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 448 participants. The study started on 2024-11-19. Estimated completion is 2027-05-31.
What conditions does trial NCT06702449 study?
This clinical trial studies the following conditions: Urinary Tract Infections.
What interventions are being tested in trial NCT06702449?
The interventions under investigation include: Candidate UTI vaccine low dose formulation 1 (COMBINATION_PRODUCT), Candidate UTI vaccine low dose formulation 2 (COMBINATION_PRODUCT), Candidate UTI vaccine medium dose formulation 1 (COMBINATION_PRODUCT), Candidate UTI vaccine medium dose formulation 2 (COMBINATION_PRODUCT), Candidate UTI vaccine high dose formulation 1 (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06702449?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06702449 being conducted?
This trial has 8 study locations across Kansas, New Jersey, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Tract Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection
COMPLETED · Phase 1
-
Treatment and/or Prevention of Urinary Tract Infections
COMPLETED · Phase 1
-
Application of a Prediction Model for Directing Antibiotic Use in the Treatment of Urinary Tract Infection in an Ambulatory Setting
RECRUITING · NA
-
NextGen - Clinical Implication of Next Generation Sequencing
RECRUITING · Phase 4
-
Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial
RECRUITING · NA
-
Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.